自体造血干细胞移植联合利妥昔单抗治疗CD20^＋B细胞淋巴瘤

Rituximab combined with autologous hematopoietic stem cell transplantation for therapy of CD20 positive B-cell lymphoma

采用自体造血干细胞移植（AHSCT）治疗中、高危侵袭性淋巴瘤已获得了较好疗效，但仍有部分移植患者因复发而死亡。复发的根源主要为微小残留病变，包括体内残留的肿瘤细胞和移植物中的肿瘤细胞污染。利妥昔单抗可靶向性清除CD20^＋B细胞，因此，对CD20^＋B细胞淋巴瘤患者，移植前后应用利妥昔单抗可起到体内净化和清除残留病灶作用，AHSCT联合利妥昔单抗有望进一步提高CD20^＋B细胞淋巴瘤的疗效。

Autologous hematopoietic stem cell transplantation（AHSCT） has a good curative effect for high-risk or middle-risk aggressive lymphoma, but some patients who receive AHSCT still died of recurrence. The main reason for this is the presence of minimal residual disease （MRD）, including residual tumor cells in vivo and contamination of grafts with tumor cells. Rituximab can be targeted to remove CD20 positive B cells, so application of rituximab before and after AHSCT may play a role in removal of residual disease and in vivo purging. Rituximab combined with AHSCT may further enhance the curative effect for CD20 positive B cell lymphoma.